<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1821</td>
<td>The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?</td>
<td>Michael A. Postow, Margaret K. Callahan, and Jedd D. Wolchok</td>
</tr>
<tr>
<td>1824</td>
<td>Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib</td>
<td>Augusto Villanueva and Josep M. Llovet</td>
</tr>
<tr>
<td>1827</td>
<td>In Search of a Real &quot;Targeted&quot; Therapy for Thyroid Cancer</td>
<td>Marcia S. Brose</td>
</tr>
<tr>
<td>1830</td>
<td>New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy</td>
<td>Mei Dong, Alexandria T. Phan, and James C. Yao</td>
</tr>
<tr>
<td>1837</td>
<td>Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review</td>
<td>Shiro Tanaka, Yousuke Kinjo, Yoshiki Katoaka, Kenichi Yoshimura, and Satoshi Teramukai</td>
</tr>
<tr>
<td>1848</td>
<td>Abiraterone in Prostate Cancer: A New Angle to an Old Problem</td>
<td>Mark N. Stein, Susan Goodin, and Robert S. DiPaola</td>
</tr>
<tr>
<td>1863</td>
<td>Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance</td>
<td>Kevin G. Chen and Branimir I. Sikic</td>
</tr>
<tr>
<td>1870</td>
<td>Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors</td>
<td>Carlo Visco, Francesco Maura, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Elisabetta Novela, Ilaria Giaretta, Gianluigi Reda, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, and Agostino Corteazzi</td>
</tr>
<tr>
<td>1879</td>
<td>MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p38 MAP Kinase and ETV1</td>
<td>Peter Birner, Andrea Beer, Ursula Vina, Susanne Stary, Romana Höfler, Nadine Nirtl, Fritz Wrba, Berthold Streubel, and Sebastian F. Schoppmann</td>
</tr>
<tr>
<td>1888</td>
<td>Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response</td>
<td>Sabrina Manni, Alessandra Brancalino, Laura Quotti Tubi, Anna Colpo, Laura Pavani, Anna Cabrelle, Elisa Ave, Fortunato Zaffino, Giovanni Di Maira, Maria Ruzzene, Fausto Adami, Renato Zambello, Maria Rita Piatari, Pierfrancesco Tassone, Lorenzo A. Pinna, Carmela Gurrieri, Gianpiero Semenzato, and Francesco Piazza</td>
</tr>
</tbody>
</table>
**1914** L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non–Small Cell Lung Cancer
Josephine Hai, Chang-Qi Zhu, Bizhan Bandarchi, Yu-Hui Wang, Roya Navab, Frances A. Shepherd, Igor Jurisica, and Ming-Sound Tsao

**1925** Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4⁺Foxp3⁺ Regulatory T Cells and PD-1/PD-L1/L2 Expression
Lynda J. Hatam, James A. DeVoti, David W. Rosenthal, Fung Lam, Allan L. Abramson, Bettie M. Steinberg, and Vincent R. Bonagura

**1936** Integrative Genomics Identified RFC3 As an Amplified Candidate Oncogene in Esophageal Adenocarcinoma

**1947** Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu, Hang Li, Lei Wang, William Pao, and Haiquan Chen

**IMAGING, DIAGNOSIS, PROGNOSIS**

**1992** Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer
Alain Mangé, Jérôme Lacombe, Caroline Bascoul-Mollevi, Marta Jarlier, Pierre-Jean Lamy, Philippe Rouanet, Thierry Maudelonde, and Jérôme Solassol

**2001** Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children’s Cancer Leukaemia Group (CCLG), Société Française d’Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)

**2012** A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Idoia Garcia, Gemma Domenech, Kai-Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galvan, Carmen de Torres, Jaime More, and Cinzia Lavarino

**2014** 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
CANCER THERAPY: CLINICAL

2039
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto, James C. Yang, Richard M. Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald E. White, Catherine L. Levy, Steven A. Rosenberg, and Giao Q. Phan
See commentary p. 1821

2048
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth, Cher Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, and Antonio Jimeno

2056
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
See commentary p. 1827

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2108
Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic, Padraig Warde, Cynthia Ménard, Peter Chung, Ants Toi, Adrian Ishkanian, Michael McLean, Melanie Pintilie, Jenna Sykes, Mary Gospodarowicz, Charles Catton, Richard P. Hill, and Robert Bristow

CORRECTIONS

2115
Correction: Molecular Imaging of TGFβ-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGFβ Signaling
ABOUT THE COVER

High-level EGFR gene amplification can be retained in glioblastoma stem-like cell lines established and propagated without recombinant EGF. In contrast, high-level amplification is lost in parallel cell lines from the same tumors established with EGF supplementation. Cell lines with high-level EGFR amplification produce highly aggressive xenograft tumors in the brains of nude mice, retaining the EGFR amplification as shown in the cover figure, whereas counterpart cell lines, lacking high-level amplification, are either nontumorigenic or grow significantly more slowly in vivo. For details, see the article by Schulte and colleagues on page 1901 of this issue.